ImmuCell Corporation (ICCC)Healthcare | Biotechnology | Portland, United States | NasdaqCM
7.98 USD
+0.44
(5.836%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.83 -0.15 (-0.150%) ⇩ (April 17, 2026, 4:51 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:48 p.m. EDT
ImmuCell shows strong short-term momentum driven by a 13% surge and a 28.4% Q1 sales jump, trading 22% above its 50-day average, but this is balanced by negative fundamentals and an absence of dividends. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.029923 |
| AutoETS | 0.029930 |
| MSTL | 0.030930 |
| AutoTheta | 0.033773 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 97% |
| H-stat | 0.71 |
| Ljung-Box p | 0.048 |
| Jarque-Bera p | 0.320 |
| Excess Kurtosis | 1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 48.768 |
| Revenue per Share | 3.063 |
| Market Cap | 72,193,456 |
| Forward P/E | -72.55 |
| Beta | 0.31 |
| Profit Margins | -3.76% |
| Website | https://immucell.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.48327136 |
| Address1 | 56 Evergreen Drive |
| All Time High | 21.875 |
| All Time Low | 0.40625 |
| Ask | 7.13 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 38,850 |
| Average Daily Volume3 Month | 18,770 |
| Average Volume | 18,770 |
| Average Volume10Days | 38,850 |
| Beta | 0.309 |
| Bid | 7.72 |
| Bid Size | 1 |
| Book Value | 2.991 |
| City | Portland |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.98 |
| Current Ratio | 4.259 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.23 |
| Day Low | 7.52 |
| Debt To Equity | 48.768 |
| Display Name | ImmuCell |
| Earnings Call Timestamp End | 1,778,850,000 |
| Earnings Call Timestamp Start | 1,778,850,000 |
| Earnings Timestamp | 1,778,788,800 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | 5,178,906 |
| Ebitda Margins | 0.18733999 |
| Enterprise To Ebitda | 15.753 |
| Enterprise To Revenue | 2.951 |
| Enterprise Value | 81,581,008 |
| Eps Forward | -0.11 |
| Eps Trailing Twelve Months | -0.12 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.5852 |
| Fifty Day Average Change | 1.3948002 |
| Fifty Day Average Change Percent | 0.21180832 |
| Fifty Two Week Change Percent | 48.327137 |
| Fifty Two Week High | 8.23 |
| Fifty Two Week High Change | -0.24999952 |
| Fifty Two Week High Change Percent | -0.030376615 |
| Fifty Two Week Low | 4.52 |
| Fifty Two Week Low Change | 3.46 |
| Fifty Two Week Low Change Percent | 0.7654867 |
| Fifty Two Week Range | 4.52 - 8.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 547,219,800,000 |
| Float Shares | 6,015,850 |
| Forward Eps | -0.11 |
| Forward P E | -72.545456 |
| Free Cashflow | 998,360 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 73 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.41402 |
| Gross Profits | 11,445,203 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.32102 |
| Held Percent Institutions | 0.20362 |
| Implied Shares Outstanding | 9,046,799 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.immucell.com/ir-facts.html |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 648,864,000 |
| Last Split Factor | 1:100 |
| Long Business Summary | ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. |
| Long Name | ImmuCell Corporation |
| Market | us_market |
| Market Cap | 72,193,456 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_29789 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -1,040,027 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 72,193,456 |
| Open | 7.53 |
| Operating Cashflow | 2,475,292 |
| Operating Margins | 0.09729999 |
| Payout Ratio | 0.0 |
| Phone | 207 878 2770 |
| Post Market Change | -0.1500001 |
| Post Market Change Percent | -1.8797004 |
| Post Market Price | 7.83 |
| Post Market Time | 1,776,459,099 |
| Previous Close | 7.54 |
| Price Hint | 2 |
| Price To Book | 2.668004 |
| Price To Sales Trailing12 Months | 2.611525 |
| Profit Margins | -0.03762 |
| Quick Ratio | 1.824 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.44000006 |
| Regular Market Change Percent | 5.8355446 |
| Regular Market Day High | 8.23 |
| Regular Market Day Low | 7.52 |
| Regular Market Day Range | 7.52 - 8.23 |
| Regular Market Open | 7.53 |
| Regular Market Previous Close | 7.54 |
| Regular Market Price | 7.98 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 46,419 |
| Return On Assets | 0.03494 |
| Return On Equity | -0.038110003 |
| Revenue Growth | -0.016 |
| Revenue Per Share | 3.063 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 9,046,799 |
| Shares Percent Shares Out | 0.0038 |
| Shares Short | 34,248 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 15,924 |
| Short Name | ImmuCell Corporation |
| Short Percent Of Float | 0.0046 |
| Short Ratio | 2.52 |
| Source Interval | 15 |
| State | ME |
| Symbol | ICCC |
| Total Cash | 3,806,831 |
| Total Cash Per Share | 0.421 |
| Total Debt | 13,194,384 |
| Total Revenue | 27,644,174 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.249 |
| Two Hundred Day Average Change | 1.731 |
| Two Hundred Day Average Change Percent | 0.2770043 |
| Type Disp | Equity |
| Volume | 46,419 |
| Website | https://immucell.com |
| Zip | 4,103 |